Amaryan Gayane, Sarkisian Tamara, Tadevosyan Artashes, Braegger Christian
National Pediatrics Center for Familial Mediterranean Fever, "Arabkir" Medical Complex-Institute of Child and Adolescent Health, Yerevan, Armenia.
Department of Pediatrics, Yerevan State Medical University, Yerevan, Armenia.
Front Pediatr. 2024 Feb 12;11:1288523. doi: 10.3389/fped.2023.1288523. eCollection 2023.
Inflammatory bowel disease (IBD) and familial Mediterranean fever (FMF) are inflammatory diseases with complex interactions among genetic, immune, and environmental factors. FMF is a monogenic autoinflammatory disease, characterized by recurrent febrile attacks and polyserositis, and is manifested mainly in childhood. FMF is widespread in Armenia. There are reports on the concurrent occurrence of FMF and IBD. gene mutations may have a disease-modifying effect on IBD. We have investigated the frequency of mutations and FMF in Armenian children with IBD and their influence on the clinical course. A total of 69 untreated IBD patients under 18 years of age were enrolled: 52.1% (36) had ulcerative colitis (UC), 21.7% (15) had Crohn's disease (CD), and 26.0% (18) had unclassified colitis (IBD-U). The frequency of FMF among them was 36.2% (25/69), and mutations were identified in 53.6% (37/69). The highest rate of mutations and FMF was in UC patients (61.1% and 41.6% respectively). In all, 56.7% (21/37 of IBD patients with mutations had mutated alleles, mainly in compound heterozygous and heterozygous states. There were no associations in the group of IBD patients with coexisting FMF (25), either between any mutation and type of IBD or coexistence of FMF. Overall, 36.0% (9/25) of them developed VEO IBD and carried mainly the mutation. We concluded that the carrier frequency of mutations among Armenian pediatric IBD patients was rather high (53.6%), especially for UC. It was suggested that the MEFV gene is not necessarily a susceptibility gene but most likely modifies the course of IBD. genetic testing was recommended for Armenian pediatric IBD patients, especially for VEO UC and IBD-U, atypical IBD course, or resistance to the conventional treatment. They should also be asked for isolated febrile attacks, recurrent arthritis, and family history, even in the absence of FMF typical symptoms, to rule out FMF and its complications.
炎症性肠病(IBD)和家族性地中海热(FMF)是遗传、免疫和环境因素之间存在复杂相互作用的炎症性疾病。FMF是一种单基因自身炎症性疾病,其特征为反复发热发作和多浆膜炎,主要在儿童期发病。FMF在亚美尼亚广泛流行。有关于FMF与IBD同时发生的报道。某些基因突变可能对IBD有疾病修饰作用。我们调查了亚美尼亚IBD儿童中这些基因突变的频率及其对临床病程的影响。共纳入69例18岁以下未经治疗的IBD患者:52.1%(36例)患有溃疡性结肠炎(UC),21.7%(15例)患有克罗恩病(CD),26.0%(18例)患有未分类结肠炎(IBD-U)。其中FMF的发生率为36.2%(25/69),在53.6%(37/69)的患者中检测到基因突变。UC患者中基因突变和FMF的发生率最高(分别为61.1%和41.6%)。总体而言,56.7%(37例IBD患者中有21例)有基因突变的患者存在突变等位基因,主要为复合杂合子和杂合子状态。在同时患有FMF的IBD患者组(25例)中,任何基因突变与IBD类型或FMF共存之间均无关联。总体而言,其中36.0%(9/25)发展为极早发型IBD,主要携带该基因突变。我们得出结论,亚美尼亚儿科IBD患者中基因突变的携带频率相当高(53.6%),尤其是UC患者。提示MEFV基因不一定是易感基因,但很可能会改变IBD的病程。建议对亚美尼亚儿科IBD患者进行基因检测,尤其是极早发型UC和IBD-U患者、非典型IBD病程患者或对传统治疗耐药的患者。即使没有FMF的典型症状,也应询问他们是否有孤立性发热发作、复发性关节炎和家族史,以排除FMF及其并发症。